Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q3 FY23 Earnings Presentation
29 slides from Shilpa Medicare's earnings presentation, Feb 15, 2023
Slide 1: Exchange filing cover letter
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 15 February 2023 Corporate Relationship Departme
Slide 2: Q3 & 9M FY23 Results Presentation
Shilpa Medicare Limited (SML) Q3 & 9M FY23 Results Presentation 1
Slide 3: Disclaimer
2 Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and API Units, Raichur many other factors that could cause our actual
Slide 4: Table of content
Table of content 3 1 Company Overview 2 Financial Performance 3 Business Highlights 4 Annexures
Slide 5: Company Overview
Company Overview 4
Slide 6: Company Overview
Company Overview 5 Pursuing niche growth businesses like Biologics, Transdermal & Oral Dissolving Films Formulations Established presence in Active Pharmaceutical Ingredients (APIs) and Formulations for Affordable & Robust research domestic & international markets Effective orientation resulting in
Slide 7: Managing Director's Message
Managing Director’s Message 6 Commenting on Q3 FY’23 performance, Mr. Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said “We have had a steady quarter with a flat top line compared to the previous quarter. However, we have been able to improve our profitability profile based on our f
Slide 8: Financial Performance
Financial Performance 7
Slide 9: Statement of Profit and Loss-SML Standalone
Statement of Profit and Loss-SML Standalone 8 Particulars Q3 FY23 Q2 FY23 % change Q3 FY22 % change 9M FY23 9M FY22 % change (INR in Cr.) Revenues 69.2 86.8 (20.3) 99.6 (30.5) 229.5 314.6 (27.1) Gross Margin 54.7 54 1 86.3 (36.6) 172.7 246.4 (29.9) Gross Margin % 79% 62% - 87% - 75% 78% - Employee C
Slide 10: Balance Sheet-SML Standalone
Balance Sheet-SML Standalone 9 Standalone (INR in Cr.) Particulars 31-Dec-22 30-Sep-22 31-Dec-21 Fixed Assets 602.2 603.0 882.1 Tangible Assets 505.1 509.0 834.8 Intangible Assets 97.1 94.0 47.3 Capital WIP 246.9 251.5 351.2 Tangible Assets 49.1 54.1 116.3 Intangible Assets 197.8 197.4 234.9 Other N
Slide 11: Profit and loss account - Consolidated
Profit and loss account - Consolidated 10 Particulars Q3 FY23 Q2 FY23 % change Q3 FY22 % change 9M FY23 9M FY22 % change (INR in Cr.) Revenues 265.2 267.3 (0.8) 277.8 (4.5) 801.8 813.7 (1.5) Gross Margin 159.7 150.3 6.3 186.4 (14.3) 475.3 544 (12.6) Gross Margin % 60% 56% - 67% - 59% 67% - Employee
Slide 12: Balance Sheet - Consolidated
Balance Balance SheetSheet - Consolidated Consolidated 11 Consolidated (INR in Cr.) Particulars 31-Dec-22 30-Sep-22 31-Dec-21 Fixed Assets 1,365.6 1,353.7 1,345.6 Tangible Assets 1,161.8 1,154.4 1,184.9 Intangible Assets 203.8 199.3 160.8 Capital WIP 625.4 603.0 471.6 Tangible Assets 319.6 302.4 166
Slide 13: Business Highlights
Business Highlights 12
Slide 14: Q3 & 9M FY'23 Consolidated Performance
Q3 & 9M FY’23 Consolidated Performance 13 (INR in Cr.) Revenue EBIDTA -5% -1% -33% -57% -1% 105% 277.8 813.7 138.9 50.6 34.0 79.3 267.3 265.2 801.8 16.6 % to Sales 6% 13% 18% 10% 17% Q2 FY'23 Q3 FY'23 Q3 FY'22 9M FY'23 9M FY'22 Q2 FY'23 Q3 FY'23 Q3 FY'22 9M FY'23 9M FY'22 PBT PAT 20.0 47.0 9.6 32.7
Slide 15: Consolidated Revenue Break-up – Q3 FY'23
Consolidated Revenue Break-up – Q3 FY’23 14 (INR in Cr.) Q2 FY’23 Q3 FY’23 Q3 FY’22 INR 267.3cr. INR 265.2cr. INR 277.8cr. Degrowth of 5% vs Q3 FY’22 4.9, 2% 11.7, 4% 7.9, 3% 70.1 , 26% 87.3 , 31% 59.5 , 23% 192.3 , 72% 194.0 , 73% 182.6 , 66% API Formulation Others Degrowth of 1% vs Q2 FY’23
Slide 16: Consolidated Revenue Break-up – 9M FY'23
Consolidated Revenue Break-up – 9M FY’23 15 (INR in Cr.) 9M FY’23 9M FY’22 INR 801.8cr. INR 813.6cr. Degrowth of 1% vs 9M FY’22 29.5, 4% 12.9, 1% 201.8 , 25% 282.0 , 35% 570.5 , 71% 518.7 , 64% API Formulation Others
Slide 17: API Business
API Business | noting affordable healthcare
Slide 18: API Business-Highlights Q3 FY'23
API Business-Highlights Q3 FY’23 17 (INR in Cr.) Oncology CDMO/Service CRAMS -7% -16% -11% -65% -59% 214% 100.9 5.4 96.8 24 90.2 2.2 9.9 8.3 % % 0.7 % contribution contribution contribution 50% 47% 55% of API Sales 3% 1% 0.3% 5% 4% 12% of API Sales of API Sales Q2 FY'23 Q3 FY'23 Q3 FY'22 Q2 FY'23 Q3
Slide 19: API Business-Highlights 9M FY'23
API Business-Highlights 9M FY’23 18 (INR in Cr.) Oncology License Fees/PDC CRAMS -8% 168% -56% 313.6 12.6 53.8 287.9 4.7 % 23.5 % % contribution contribution contribution 51% 2% 4% 10% of API Sales 61% of API Sales 1% of API Sales FY'23 9M FY'22 9M FY'23 9M FY'22 9M FY'23 9M FY'22 9M Non Oncology Ot
Slide 20: DMF Filing update
DMF Filing update 19 New product introduction and increase in geographical coverage replicated with 224 number of DMF filings done with major regulatory authorities 49 45 33 20 19 17 12 11 9 7 2 US FDA EU/ EMEA GCC / ROW MFDS TPD-Canada TGA CHINA PMD RUSSIA MEDSAFE WHO As on 31 Dec 2022
Slide 21: Formulation Business
20 Formulation Business
Slide 22: Formulation Business-Highlights Q3 FY'23
Formulation Business-Highlights Q3 FY’23 21 (INR in Cr.) Europe License Fees/PDC ROW 27% 23% -21% 153% 120% -40% 55.8 1.4 1.1 14.7 26.5 33.6 12.0 0.5 % % 5.8 % contribution contribution 17% 25% 7% contribution 1% 38% 56% 64% 2% 2% of For. Sales of For. Sales of For. Sales Q2 FY'23 Q3 FY'23 Q3 FY'22
Slide 23: Formulation Business-Highlights 9M FY'23
Formulation Business-Highlights 9M FY’23 22 (INR in Cr.) Europe License Fees/PDC ROW -35% 108% -35% 137.1 4.0 88.7 59.8 28.8 2.6 % % % contribution 44% contribution 10% contribution 1% 49% 30% 1% of For. Sales of For. Sales of For. Sales FY'23 9M FY'22 9M FY'23 9M FY'22 9M FY'23 9M FY'22 9M US Domes
Slide 24: Regulatory Filings
Regulatory Filings 23 Robust regulatory filings to strength the base for growth in the formulation segment Approved Pending 376 28 26 6 223 13 18 5 22 13 3 13 153 2 1 US ANDA (SML) US NDA (SML) US ANDA (Customer) EU Filings ROW As on 31 Dec 2022
Slide 25: Annexures
Annexures 24
Slide 26: Manufacturing Excellence
Manufacturing Excellence 25 Dharwad Jadcherla Unit • Biologicals Manufacturing plant & R&D • Formulations (Onco & Adjuvant Therapy Facility • of Onco – Injectable & Oral) Bengaluru Unit Hyderabad • Formulations (Oral Dissolving Films) • TDS & ODF Manufacturing Facility & • Bio Analytical Lab, Pharma
Slide 27: Giving back to society
Giving back to society 26 Shilpa Medicare Limited works with Shilpa Foundation to carry out various CSR activities below are few of the many activities carried out in Q3 FY’23 Conducted Health camp for TB patients and donated the nutrition powder to needy TB patients for in Raichur District TB cell
Slide 28: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. 27 Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated marke
Slide 29: Thank You
28 Thank You